Milestones in the development of Lym-1 therapy

Hybridoma

Volumn 18, Issue 1, 1999, Pages 1-11

  DeNardo, Gerald L ^a,c   O'Donnell, Robert T ^a   Rose, Larry M ^b   Mirick, Gary R ^a   Kroger, Linda A ^a   DeNardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Molecular Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR ANTIGEN; IMMUNOGLOBULIN IDIOTYPE; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM 1; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PROTOCOL; CONFERENCE PAPER; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RADIODIAGNOSIS; RADIOIMMUNOTHERAPY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANIMALIA;

EID: 0033065954     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1999.18.1     Document Type: Conference Paper

References (46)

1. DeNardo SJ, DeNardo GL, O'Grady LF, et al.: Treatment of a patient with B cell lymphoma by I-131 Lym-1 monoclonal antibodies. Int J Biol Markers 1987;2:49-53.
2. DeNardo SJ, DeNardo GL, O'Grady LF, et al.: Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antibody Immunoconj Radiopharm 1988;1:17-33.
3. Czuczman MS, Straus DJ, Divgi CR, et al.: Phase 1 dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 1993;11: 2021-2029.
4. DeNardo GL, DeNardo SJ, O'Grady LF, Levy NB, Adams GP, and Mills SL: Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. Cancer Res 1990;50 (Suppl):1014-1016.
5. DeNardo GL, Lewis JP, DeNardo SJ, and O'Grady LF: Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 1994;73:1425-1432.
6. Kaminski MS, Zasadny KR, Francis IR, et al.: Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-465.
7. Kaminski MS, Zasadny KR, Francis FR, et al.: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974-1981.
8. Press OW, Eary JF, Appelbaum FR, et al.: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-1224.
9. Press OW, Eary JF, Appelbaum FR, et al.: Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995;346: 336-340.
10. Rose LM, Gunasekera AH, DeNardo SJ, DeNardo GL, and Meares CF: Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother 1996;43:26-30.
11. Epstein AL, Marder RJ, Winter JN, et al.: Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987;47:830-840.
12. DeNardo SJ, DeNardo GL, O'Grady LF, et al.: Treatment of B cell malignancies with I-131 Lym-1 monoclonal antibodies. Int J Cancer 1988;3(Suppl):96-101.
13. Schlom J, Molinolo A, Simpson JF, et al.: Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 1990;82:763-771.
14. 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model. Int J Cancer 1988;41:127-134.
15. Buchsbaum DJ, Khazaeli MB, Liu TP, and Bright S: Fractionated radioimmunotherapy of human colon carcinoma xenografts with I-131-labeled monoclonal antibody CC49. Cancer Res 1995;55(Suppl): 5881-5887.
16. Meredith RF, Khazaeli MB, Liu T, et al.: Dose fraction of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 1992;33:648-1653.
17. DeNardo SJ, Kroger LA, MacKenzie MR, Mirick GR, Shen S, and DeNardo GL: Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody. Cancer Biother Radiopharm 1998;13:1-12.
18. Hu E, Epstein AL, Naeve GS, et al.: A phase 1a clinical trial of Lym-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol Oncol 1989;7:155-166.
19. Lechler RI, Simpson E, and Bach F: Major and minor histocompatibility antigens. In: Transplantation Immunology. Bach F, Auchincloss H. (Eds.). Wiley-Liss, New York, 1995, pp. 1-34.
20. Granja CB, Salazar M, and Yunis EJ: Population genetics and human leukocyte antign polymorphism. In: Transplantation Biology: Cellular and Molecular Aspects. Tilney NL, Strom TB, Paul LC. (Eds.). Lippincott-Raven, Philadelphia, 1996.
21. Abdulkadir SA, Casolaro V, Schwiebert LS, et al.: Histocompatibility complex and their transcriptional regulation. In: MHC Molecules: Expression, Assembly and Function. Urban RG, Chicz RM. (Eds.). Landes, Austin, 1995.
22. So A: Genetics, polymorphism, and regulation of expression of HLA region genes. In: HLA and Disease. Lechler R. (Ed.). Academic Press, Boston, 1994, p. 18.
23. Brown J, McCloskey D, and Navarrete C: HLA-DR and -DQ serotyping. In: Handbook of HLA Typing Techniques. Hui K, Bidwell J. (Eds.). CRC Press, Boca Raton, 1993.
24. HLA 1991: Proceedings of the 11th International Histocompatibility Workshop and Conference. New York, Oxford University Press, 1992.
25. DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, and DeNardo SJ: Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Cancer 1997;80(Suppl):2706-2711.
26. Adams GP, DeNardo SJ, Amin A, et al.: Comparison of the pharmacokinetics in mice and the biological activity of murine L6 and human-mouse chimeric Ch-L6 antibody. Antibody Immunoconj Radiopharm 1992;5:81-95.
27. 131I-Lym-1 and 67Cu-2IT-BAT-Lym-1 and opportunities for improvement. In: Cancer Therapy with Radiolabeled Antibodies. Goldenberg DM. (Ed.). CRC Press, Boca Raton, FL, 1994, pp. 217-227.
28. Knox SJ, Goris ML, and Wessels BW: Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Radiother Oncol 1992;23:111-117.
29. Macklis RM, Beresford BA, and Humm JL: Radiobiologic studies of low-dose rate 90Y lymphoma therapy. Cancer 1994;73(Suppl): 966-973.
30. Winthrop MD, DeNardo SJ, Muenzer JT, Chi SG, and Gumerlock PH: p53-independent response of a human breast cancer xenograft to radioimmunotherapy. Cancer 1997;80(Suppl):2706-2712.
31. Fowler JF: Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys 1990;18:1261-1269.
32. Lamborn KR, DeNardo GL, DeNardo SJ, Goldstein DS, Larkin EC, and Kroger LA: Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies. Clin Cancer Res 1997;3:1253-1260.
33. Jerne NK: Towards a network theory of the immune system. Ann Immunol (Paris) 1974;125C:373-389.
34. Sears HF, Atkinson B, Mattis J, et al.: Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumors. Lancet 1982;1(8275):762-765.
35. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al.: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group [see comments]. Lancet 1994;343:1177-1183.
36. Wagner U, Reinsberg J, Oehr P, et al.: Clinical course of patients with ovarian carcinomas after the induction of anti-idiotypic antibodies against a tumor associated antigen. An approach to immunotherapy of advanced ovarian cancer. Tumot Diagnostik Therapie 1990;11:1-7.
37. Wagner UA, Oehr PF, Reinsberg J, et al.: Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network. Biotechnol Therapeut 1992;3:81-89.
38. Baum RP, Neisen A, Hertel A, et al.: Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 1994;1:73(Suppl 3):1121-1125.
39. Koprowski H, Herlyn D, Lubeck M, DeFreitas E, and Sears H: Human anti-idiotype in cancer patients: Is the modulation of the immune response beneficial for the patient. Proc Natl Acad Sci USA 1984;81:216-219.
40. Herlyn D, Wettendorff M, Schmoll E, et al.: Anti-idiotype immunization of cancer patients: Modulation of the immune response. Proc Natl Acad Sci USA 1987;84:8055-8059.
41. Herlyn D, Wettendorff M, Iliopoulos D, Schmoll E, Schedel I, and Koprowski H: Modulation of cancer patients' immune responses by administration of anti-idiotypic antibodies. Viral Immunol 1989;2:271-276.
42. Mittelman A, Wang X, Matsumoto K, and Ferrone S: Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Hybridoma 1995;14:175-181.
43. Foon KA, Chakraborty M, John WJ, Sherratt A, Kohler H, and Bhattacharya-Chatterjee M: Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest 1995;96:334-342.
44. Herlyn D, Ross AH, and Koprowski H: Anti-idiotypic antibodies bear the internal image of a human tumor antigen. Science 1986;232:100-102.
45. Herlyn D, Zaloudik J, Somasundaram R, Jacob L, Benden A, and Mastangelo M: Anti-idiotype vaccine in colorectal cancer patients. Hybridoma 1993;12:515-520.
46. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, and Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992;327:1209-1215.